April 19, 2026

Adcendo Series C: $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

ADCendo

Investment raised

USD 75m

Valuation

Stage

Region

Investors

The round was led Jeito Capital, with participation from additional new investors Vida Ventures, BPI France, and EIFO (Export and Investment Fund of Denmark), as well as all existing investors, including TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, a platform controlled by KKR, HealthCap, Gilde Healthcare and Ysios Capital.

Multiples

ADCendo operates in the biotechnology and pharmaceutical sector, developing targeted therapies at the intersection of advanced science and precision medicine. In line with its Series C stage, European benchmarks (Q4 2025) for Biotech and Pharmaceuticals indicate valuation ranges of EV/Sales 3.71x – 4.74x and EV/EBITDA 19.32x – 21.52x.